Journal of the Neurological Sciences
Volume 288, Issue 1 , Pages 186-189 , 15 January 2010

Possible removal of topiramate by continuous renal replacement therapy

  • Linda Browning

      Affiliations

    • Detroit Receiving Hospital, Department of Pharmacy, Detroit, Michigan, USA
    • ,
  • Dennis Parker Jr.

      Affiliations

    • Wayne State University, Eugene Applebaum College of Pharmacy & Health Sciences, Detroit, Michigan, USA
    • ,
  • Xi Liu-DeRyke

      Affiliations

    • Orlando Regional Medical Center, Department of Pharmacy, Orlando, Florida, USA
    • ,
  • Aashit Shah

      Affiliations

    • Wayne State University College of Medicine, Department of Neurology, Detroit Receiving Hospital, Detroit, Michigan, USA
    • ,
  • William M. Coplin

      Affiliations

    • Wayne State University College of Medicine, Departments of Neurology and Neurological Surgery, Neuroscience Intensive Care Unit, Detroit Receiving Hospital, Detroit, Michigan, USA
    • ,
  • Denise H. Rhoney

      Affiliations

    • Wayne State University, Eugene Applebaum College of Pharmacy & Health Sciences, 259 Mack Avenue, Detroit, MI 48201, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 313 993 7742; fax: +1 313 577 5369.

Received 17 February 2009 ,Revised 18 August 2009 ,Accepted 7 October 2009.

References 

  1. Davenport A. Renal replacement therapy in the patient with acute brain injury. Am J Kidney Dis. 2001;37(3):457–466
  2. Claassen J, Mayer SA, Kowalski RG, Emerson RG, Hirsch LJ. Detection of electrographic seizures with continuous EEG monitoring in critically ill patients. Neurology. 2004;62(10):1743–1748
  3. Kahriman M, Minecan D, Kutluay E, Selwa L, Beydoun A. Efficacy of topiramate in children with refractory status epilepticus. Epilepsia. 2003;44(10):1353–1356
  4. Perry MS, Holt PJ, Sladky JT. Topiramate loading for refractory status epilepticus in children. Epilepsia. 2006;47(6):1070–1071
  5. Towne AR, Garnett LK, Waterhouse EJ, Morton LD, DeLorenzo RJ. The use of topiramate in refractory status epilepticus. Neurology. 2003;60(2):332–334
  6. Gisclon LG, Curtin CR. The pharmacokinetics (PK) of topiramate (T) in subjects with end-stage renal disease undergoing hemodialysis [Abstract]. Clin Pharmacol Ther. 1994;55:196
  7. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med. 1996;334(22):1448–1460
  8. Joy MS, Matzke GR, Armstrong DK, Marx MA, Zarowitz BJ. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother. 1998;32(3):362–375
  9. Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations. Clin Pharmacokinet. 1993;24(5):362–379
  10. Gisclon LG, Riffitts JM, Sica DA, Gehr T, Ruddley J. The pharmacokinetics (PK) of topiramate (T) in subjects with renal impairment (RI) as compared to matched subjects with normal renal function (NRF). Pharm Res. 1993;10:S397;Isuppl
  11. Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia. 2000;41(Suppl 1):S61–S65
  12. Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet. 1996;31(1):29–46
  13. Arroyo S, Dodson WE, Privitera MD, Glauser TA, Naritoku DK, Dlugos DJ, et al. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand. 2005;112(4):214–222
  14. Baltez E, Coupez R. Levetiracetam dose adjustment for patients on hemodialysis [abstract]. Epilepsia. 2000;41(Suppl 7):254
  15. Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol. 2003;43(3):277–283
  16. French J. Use of levetiracetam in special populations. Epilepsia. 2001;42(Suppl 4):40–43
  17. Power BM, Forbes AM, van Heerden PV, Ilett KF. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet. 1998;34(1):25–56
  18. Bensalem MK, Fakhoury TA. Topiramate and status epilepticus: report of three cases. Epilepsy Behav. 2003;4(6):757–760
  19. Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia. 1996;37(8):774–780
  20. Gisclon LG, Curtin CR, Kramer LD. The steady-state (SS) pharmacokinetics (PK) of phenytoin (Dilantin®) and topiramate (Topamax TM) in epileptic patients on monotherapy, and during combination therapy. Epilepsia. 1994;35(Suppl 8):54
  21. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet. 1998;35(5):361–390
  22. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003;2(6):347–356
  23. Perucca E, Hedges A, Makki KA, Ruprah M, Wilson JF, Richens A. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. 1984. Br J Clin Pharmacol. 2004;58(7):S854–S863discussion S64-6
  24. Perucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharmacol Ther. 1987;33(1):139–144
  25. Placidi F, Tombini M, Romigi A, Bianchi L, Izzi F, Sperli F, et al. Topiramate: effect on EEG interictal abnormalities and background activity in patients affected by focal epilepsy. Epilepsy Res. 2004;58(1):43–52
  26. Wong MO, Eldon MA, Keane WF, Turck D, Bockbrader HN, Underwood BA, et al. Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol. 1995;35(6):622–626
  27. Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E. Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis. Drugs Exp Clin Res. 1993;19(1):25–32
  28. Ijiri Y, Inoue T, Fukuda F, Suzuki K, Kobayashi T, Shibahara N, et al. Dialyzability of the antiepileptic drug zonisamide in patients undergoing hemodialysis. Epilepsia. 2004;45(8):924–927
  29. VIMPAT (Lacosamide). Package Insert UCB, Inc, Jan 2009. Smyma, GA.

PII: S0022-510X(09)00897-1

doi: 10.1016/j.jns.2009.10.001

Journal of the Neurological Sciences
Volume 288, Issue 1 , Pages 186-189 , 15 January 2010

Article Tools

* Image Usage & Resolution